[
  {
    "ts": "2026-02-13T14:57:36+00:00",
    "headline": "Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. In another development, Guggenheim lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $975 from $865 […]",
    "url": "https://finance.yahoo.com/news/where-regeneron-pharmaceuticals-regn-headed-145736538.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8cd20ada-7200-3f51-a8ca-eb93ea0e61d0",
      "content": {
        "id": "8cd20ada-7200-3f51-a8ca-eb93ea0e61d0",
        "contentType": "STORY",
        "title": "Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?",
        "description": "",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. In another development, Guggenheim lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $975 from $865 […]",
        "pubDate": "2026-02-13T14:57:36Z",
        "displayTime": "2026-02-13T14:57:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Regeneron (REGN) Draws Higher Target From TD Cowen",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xYTEe3VE6sgZxe9COOwZXw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ku0XeMdDvNCP8FVlwzrrCw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/where-regeneron-pharmaceuticals-regn-headed-145736538.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-regeneron-pharmaceuticals-regn-headed-145736538.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]